Topical antiperspirants are considered the first-line treatment for mild to moderate focal hyperhidrosis.^15,16 These formulations most commonly contain aluminum chloride, but may also include aluminum chloride hexahydrate, aluminum sesquichlorohydrate, or aluminum lactate.^17–19 Although often categorized as conventional, aluminum-based antiperspirants can also be considered integrative due to their use of naturally occurring mineral salts, topical and localized application, and non-invasive mechanism of action. These work by forming temporary plugs within the eccrine sweat ducts, thereby reducing sweat production.¹⁷ These are typically applied nightly to affected areas such as the underarms, palms, and soles until the desired outcome is achieved, then used as needed for maintenance.¹⁷ However, their use is often limited by skin irritation, burning, or stinging, and they are generally not effective for severe cases or large treatment areas.^15,17

When topical antiperspirants are insufficient, anticholinergic medications may be used in either topical or oral forms.^19,20 These agents reduce sweat production by blocking the action of acetylcholine at muscarinic receptors on sweat glands.²⁰ Topical anticholinergic forms, including glycopyrrolate, glycopyrronium (Food and Drug Administration (FDA) approved for axillary hyperhidrosis), or oxybutynin. These are effective for localized areas like the palms, soles, axillae, and craniofacial area and are applied daily, though they may cause local irritation and have limited long-term safety data.²⁰

Oral anticholinergic agents, such as glycopyrrolate and oxybutynin, are effective in treating both focal and generalized hyperhidrosis. However, their use is often limited by systemic side effects including dry mouth, constipation, urinary retention, and blurred vision which can impact tolerability, particularly in older adults or those concurrently taking other medications with anticholinergic properties.²¹ In clinical studies, glycopyrrolate has been initiated at doses as low as 0.5 mg, titrated up to a maximum of 8 mg daily, while oxybutynin typically starts at 2.5 mg, with doses reaching up to 20 mg per day. Notably, dry mouth tends to emerge at doses of 10 mg or higher of oxybutynin.²² Anticholinergic medications are generally contraindicated in patients with glaucoma, paralytic ileus, Sjögren’s syndrome, and myasthenia gravis, as they may exacerbate symptoms associated with these conditions.¹⁹

Botulinum toxin injections are a highly effective treatment for focal hyperhidrosis, especially in the axillae, palms, and soles.²³ Botulinum toxin blocks the release of acetylcholine at the neuromuscular junction, preventing the activation of sweat glands and significantly reducing sweat production.^23,24 The injections are administered intradermally in the affected areas, typically every 4 to 6 months.²⁵ Adult studies have reported a wide dosing range of botulinum toxin from 20 to 400 units depending of the brand and location, with 50 units most commonly required to achieve anhidrosis in the axillary region.²⁵ Pediatric dosing varies by treatment site and botulinum toxin formulation, but the guidelines for Botox is up to 10 units per kilogram of body weight, with a maximum total dose of 340 units.²⁶ Although effective, this treatment presents several limitations. Injections can be painful, especially in sensitive areas such as the axillae, palms, and soles, and may lead to temporary muscle weakness, bruising, and discomfort. Additionally, the procedure is often cost prohibitive, as it may not be covered by insurance, and requires ongoing maintenance sessions to sustain results.^25,27

Surgical intervention, such as endoscopic thoracic sympathectomy (ETS), is generally reserved for severe cases of hyperhidrosis that do not respond to other treatments.^12,28 This minimally invasive procedure involves cutting, clipping, or cauterizing specific sympathetic nerves (eg, T2-T3 for palmar hyperhidrosis) to disrupt the nerve signals that trigger excessive sweating.^12,28 ETS is highly effective for treating palmar hyperhidrosis, but it carries several risks. These include compensatory sweating in other anatomical regions, infection, scarring, and pneumothorax. The latter may occur due to surgical trauma, as the procedure necessitates entry into the pleural cavity, increasing the potential for lung or pleural injury.^29,30

MiraDry (Figure 1) serves as a non-invasive, effective and generally safe treatment for primary axillary hyperhidrosis and bromhidrosis especially when compared to alternatives like drug therapies or ETS.^31,32 It gained FDA approval in 2002 for axillary hyperhidrosis and has demonstrated high patient satisfaction relative to other treatment modalities, with complete or near complete resolution of symptoms for years after 1-2 treatments.³³ The device uses microwave-based technology to deliver thermal energy to the junction between the deep dermal and subcutaneous fat layers.^13,33 This energy is selectively absorbed by tissues with high water content, allowing it to target sweat glands.^13,34,35 The resulting process, known as thermolytic obliteration, results in the destruction of eccrine and apocrine sweat glands and the surrounding deep dermis.³³ The duration of heat exposure is important as longer applications result in more extensive destruction of sweat glands.³³ Clinical studies have shown a statistically significant reduction in axillary sweat production measured both objectively and subjectively.³¹ For instance, one study reported complete resolution or minimal sweating in 86% of patients six months after a single treatment session.³¹ Treatment with the miraDry device takes 20-30 minutes per axilla with patients sometimes requiring two sessions, the second one at least three months after the first.¹³ Reported side effects are minimal and temporary, such as swelling and redness.³² However, rare, but more serious and even fatal complications have been reported in case reports, including necrotizing fasciitis, brachial plexus injury, and inflammatory nodules.^36–38 An additional limitation is its high cost, especially when compared to topical therapies.³⁵ Moreover, it is only FDA-approved for axillary hyperhidrosis, limiting its use for other regions of the body.¹³ Despite these rare adverse events and limitations, MiraDry is generally considered safe when used appropriately for axillary hyperhidrosis.³⁵

Figure 1.

Although these other treatments can offer symptomatic relief, iontophoresis stands out as a non-invasive and potentially drug-free option that can be highly effective.³ Iontophoresis, first introduced in the 1930s, has consistently demonstrated both safety and efficacy. It can be considered a first-line therapeutic option, particularly for managing palmar and plantar hyperhidrosis.³ It involves immersing the affected area, typically the hands or feet, into a solution, often tap water or a medicated medium such as aluminum salts, glycopyrrolate, glycopyrronium bromide, or poldine methosulfate, while a mild electrical current between 15-20 mA is passed through (Figure 2).^3,40 This setup makes it less practical for axillary hyperhidrosis due to the difficulty of immersing the underarms in a medium, although some manufacturers have created specialized attachments to address these limitations.^41,42 Although the exact mechanism of action remains unclear, several theories exist. One suggests that iontophoresis may block sweat glands by promoting keratin plug formation or altering the electrochemical gradient, thereby impairing eccrine gland function. Another hypothesis proposes that the treatment causes jamming of mineral nanoparticles within the sweat ducts, temporarily halting sweat production.⁴³

Figure 2.

Studies have demonstrated that this treatment can significantly enhance quality of life, with symptom relief lasting up to three months post-treatment.³ In pediatric populations, approximately 50% of patients with primary palmar hyperhidrosis reported symptom improvement.⁴¹ Currently, there are no standardized guidelines regarding the optimal timing and frequency of sessions. These parameters may vary depending on the device manufacturer. However, treatment protocols commonly recommend 10-30-minute sessions, administered 3-5 times per week (Table 1).⁴⁵ One retrospective review observed clinical benefit after an average of 15 treatment sessions in adolescent patients.⁴² However, typically 6 to 15 treatment sessions are administered over a period of 3 to 4 weeks to achieve initial improvement. Maintenance sessions are then recommended at intervals of every 1 to 4 weeks, depending on symptom recurrence and patient response.⁴⁰ Several FDA-approved manufacturers have developed devices that show promising results. These include RA Fischer Co. Corp., Dermadry Laboratories, Hidrex GmbH, Hightech Production, s.r.o., and Saalmann Medical GmbH & Co. KG.⁴²

325554 Table 1.

Despite its advantages, iontophoresis has limitations. Although not severe and generally well tolerated, side effects can include skin dryness, redness, itching, pain, and most commonly paresthesia which are usually transient and tolerable.^3,43,46–48 One study reported that tingling began within the first 30 minutes of application but gradually subsided and resolved completely thereafter.⁴⁸ Additionally, it often requires multiple sessions before noticeable improvement which may impact patient adherence.⁴¹ Even though it might be cost-effective over time, iontophoresis devices can be expensive, with out-of-pocket costs ranging from $450 to $1,075 (Table 2). The upfront cost of purchasing an in-home device or repeated office visits can be cost-prohibitive for patients depending on their insurance coverage and resources, which can further limit accessibility.⁴¹ Furthermore, the use of iontophoresis would benefit from more randomized controlled trials to not only better understand its mechanism of action and long-term efficacy, but also to standardize treatment protocols, evaluate long-term safety, and guide device innovation.

325555 Table 2.

As previously discussed, hyperhidrosis can substantially impair psychosocial functioning, with negative effects on academic performance, occupational productivity, and social engagement. These disruptions may hinder patients’ ability to form and maintain relationships and carry out daily activities effectively.^10,11 In addition to addressing the physical manifestations of hyperhidrosis, integrating psychological support, such as consultation with an internist or psychiatrist, can be instrumental in managing the emotional and mental burden associated with the condition.⁴⁹ Notably, the relationship between hyperhidrosis and psychological stress is bidirectional: anxiety and emotional distress can exacerbate sweating, a phenomenon referred to as “emotional sweating,” which typically subsides during sleep and periods of relaxation. This interplay underscores the importance of psychiatric evaluation, stress reduction strategies, and lifestyle modifications as integral components of comprehensive hyperhidrosis care.^14,50

Given this interplay, dermatologists play a vital role not only in treating the physical symptoms but also in identifying psychological comorbidities such as generalized or social anxiety that may accompany or aggravate the disorder.⁵¹ Routine screening for mood or anxiety symptoms, empathetic discussion of emotional distress, and timely referral to internists, psychiatrists, or clinical psychologists can optimize outcomes.⁵² In addition, dermatologists can recommend mind-body interventions such as hypnosis as adjunct therapies in a comprehensive, integrated care plan.⁵³

Clinical hypnosis has shown benefit in small studies and case reports when combined with standard hyperhidrosis treatments. One study demonstrated that hypnosis improved comfort and tolerability during botulinum toxin injections for palmar hyperhidrosis.⁵⁴ Similarly, a case report described successful control of sweating and social anxiety symptoms when hypnosis was integrated with conventional therapy.⁵⁵ Though data remain preliminary, these findings lend support to the therapeutic value of hypnosis in reducing anxiety-induced sweating and enhancing procedural acceptance.

Omega-3 fatty acids are dietary supplements with a broad range of potential health benefits, including the modulation of vasomotor symptoms, such as night sweats, which may contribute to secondary hyperhidrosis in women undergoing the menopausal transition.⁵⁶ Preliminary data from a small single-blind study demonstrated a reduction in the frequency of vasomotor symptoms following omega-3 supplementation; however, the limited sample size and unclear statistical significance necessitate cautious interpretation.⁵⁶ Additional evidence suggests that omega-3 supplementation may attenuate both the frequency and intensity of vasomotor symptoms, although findings remain variable across studies.⁵⁷ Taken together, these observations support a potential therapeutic role for omega-3 fatty acids in the management of thermoregulatory disturbances, including hyperhidrosis, in this population.

This study did not require approval by the institutional review board.

The authors have no relevant conflicts of interest to disclose.